Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: A human and animal model study

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kusner, Linda L ^a   Ciesielski, Michael J ^b   Marx, Alexander ^c   Kaminski, Henry J ^a   Fenstermaker, Robert A ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE VACCINE; SURVIVIN; SURVIVIN53 67 M57 KEYHOLE LIMPET HEMOCYANIN VACCINE; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PHENOTYPE; PLASMA CELL; PROTEIN EXPRESSION; THYMUS; VACCINATION; AGED; ANIMAL; C57BL MOUSE; CASE CONTROL STUDY; DISEASE MODEL; IMMUNOLOGY; LEWIS RAT; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NEUROMUSCULAR JUNCTION; PHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; ANIMALS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKOCYTES, MONONUCLEAR; MALE; MICE, INBRED C57BL; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; THYMUS GLAND; YOUNG ADULT;

EID: 84904701212     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102231     Document Type: Article

References (44)

1. Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. The Journal of clinical investigation 116: 2843-2854. (Pubitemid 44684466)
2. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, et al. (2008) IAP-targeted therapies for cancer. Oncogene 27: 6252-6275.
3. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, et al. (2000) Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95: 1435-1442. (Pubitemid 30099858)
4. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, et al. (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43-49. (Pubitemid 28028045)
5. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584. (Pubitemid 28563719)
6. Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ (2006) Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 17: 1483-1493. (Pubitemid 43376565)
7. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, et al. (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 19: 3225-3234. (Pubitemid 30487409)
8. Altieri DC (2010) Survivin and IAP proteins in cell-death mechanisms. Biochem J 430: 199-205.
9. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, et al. (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123. (Pubitemid 32108606)
10. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320. (Pubitemid 28551107)
11. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005.
12. Sharief MK, Semra YK (2001) Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 119: 358-364. (Pubitemid 32918345)
13. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A (2005) Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 7: R349-358.
14. Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, et al. (2010) Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 49: 862-875.
15. Galeotti L, Adrian K, Berg S, Tarkowski A, Bokarewa M (2008) Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clin Exp Rheumatol 26: 373-378. (Pubitemid 351659151)
16. Isgren A, Forslind K, Erlandsson M, Axelsson C, Andersson S, et al. (2012) High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin Arthritis Rheum 41: 652-657.
17. Hebb AL, Moore CS, Bhan V, Campbell T, Fisk JD, et al. (2008) Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Mult Scler 14: 577-594. (Pubitemid 351954399)
18. Sharief MK, Noori MA, Douglas MR, Semra YK (2002) Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis. Eur J Neurol 9: 503-510. (Pubitemid 35013876)
19. Andersen MH, Pedersen LO, Becker JC, Straten PT (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61: 869-872. (Pubitemid 32175146)
20. Aguilar LK, Guzik BW, Aguilar-Cordova E (2011) Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 112: 1969-1977.
21. Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, et al. (2010) Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 59: 1211-1221.
22. Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA (2008) Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother 57: 1827-1835.
23. Fenstermaker RA, Ciesielski MJ (2014) Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma. Expert Rev Vaccines 13: 377-385.
24. Lang B, Vincent A (2009) Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol 9: 336-340.
25. Christadoss P, Poussin M, Deng C (2000) Animal models of myasthenia gravis. Clin Immunol 94: 75-87. (Pubitemid 30067872)
26. Baggi F, Antozzi C, Toscani C, Cordiglieri C (2012) Acetylcholine receptorinduced experimental myasthenia gravis: what have we learned from animal models after three decades? Archivum immunologiae et therapiae experimentalis 60: 19-30.
27. Kyewski B, Taubert R (2008) How promiscuity promotes tolerance: the case of myasthenia gravis. Ann N Y Acad Sci 1132: 157-162. (Pubitemid 351841368)
28. Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, et al. (2012) Recommendations for myasthenia gravis clinical trials. Muscle & nerve 45: 909-917.
29. Simon-Keller K, Paschen A, Hombach AA, Strobel P, Coindre JM, et al. (2013) Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells. Am J Pathol 182: 2121-2131.
30. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, et al. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490: 187-191.
31. Wu B, Goluszko E, Christadoss P (2001) Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol Chapter 15: Unit 15 18.
32. Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP (1996) Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 71: 173-177. (Pubitemid 26413270)
33. Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, et al. (2006) Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55: 1491-1503. (Pubitemid 44327837)
34. Kusner LL, Halperin JA, Kaminski HJ (2013) Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve 47: 33-40.
35. Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, et al. (2009) Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 65: 67-75.
36. Cavalcante P, Cufi P, Mantegazza R, Berrih-Aknin S, Bernasconi P, et al. (2013) Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev 12: 863-874.
37. Marx A, Pfister F, Schalke B, Nix W, Strobel P (2012) Thymus pathology observed in the MGTX trial. Ann N Y Acad Sci 1275: 92-100.
38. Tuzun E, Scott BG, Goluszko E, Higgs S, Christadoss P (2003) Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 171: 3847-3854. (Pubitemid 37264927)
39. Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, et al. (2006) The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 146: 294-302. (Pubitemid 44581345)
40. Khan WN, Wright JA, Kleiman E, Boucher JC, Castro I, et al. (2013) Blymphocyte tolerance and effector function in immunity and autoimmunity. Immunol Res 57: 335-353.
41. Ragheb S, Lisak R, Lewis R, Van Stavern G, Gonzales F, et al. (2008) A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 65: 1358-1362.
42. Thangarajh M, Masterman T, Helgeland L, Rot U, Jonsson MV, et al. (2006) The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol 178: 161-166. (Pubitemid 44316862)
43. Fujii Y, Hashimoto J, Monden Y, Ito T, Nakahara K, et al. (1986) Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis. J Immunol 136: 887-891. (Pubitemid 16146371)
44. Mobahat M, Narendran A, Riabowol K (2014) Survivin as a preferential target for cancer therapy. Int J Mol Sci 15: 2494-2516.